Journal article
Plasmodium vivax diversity and population structure across four continents
C Koepfli, PT Rodrigues, T Antao, P Orjuela-Sánchez, P van den Eede, D Gamboa, N van Hong, J Bendezu, A Erhart, C Barnadas, A Ratsimbasoa, D Menard, C Severini, M Menegon, BYM Nour, N Karunaweera, I Mueller, MU Ferreira, I Felger
Plos Neglected Tropical Diseases | Published : 2015
Open access
Abstract
Plasmodium vivax is the geographically most widespread human malaria parasite. To analyze patterns ofmicrosatellite diversity and population structure across countries of different transmission intensity, genotyping data from 11microsatellitemarkers was either generated or compiled from 841 isolates from four continents collected in 1999–2008. Diversity was highest in South-East Asia (mean allelic richness 10.0–12.8), intermediate in the South Pacific (8.1–9.9) Madagascar and Sudan (7.9–8.4), and lowest in South America and Central Asia (5.5–7.2). A reduced panel of only 3 markers was sufficient to identify approx. 90% of all haplotypes in South Pacific, African and SE-Asian populations, but..
View full abstractGrants
Awarded by Wellcome Trust
Funding Acknowledgements
This work was supported by the Brazilian Swiss Joint Research Programme (BSJRP, grant 0112-07), the Swiss National Science Foundation (www.snf.ch, grants 310030_134889, P2BSP3_151880), the International Centers of Excellence in Malaria Research (grant U19 AI089686) and the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (www.cnpq.br, grant #590106/2011-2 and senior research scholarship). The sample collection and analysis in Peru was supported by The Global Fund to fight AIDS, Tuberculosis and Malaria (www.theglobalfund.org) through the Organismo Andino de SaludConvenio Hipolito Unanue (grant MAA-305-G01-M) and by the Directorate General for Development Cooperation (DGCD) of the Belgian Government (framework agreement 03, project 95502). Sample collection in Armenia, Azerbaijan and Uzbekistan was supported by COPERNICUS-2 RTD project contract ICA2-CT-2000-10046 (VIVAXNIS) of the European Commission. This work was made possible through Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS. TA is funded by a Sir Henry Wellcome postdoctoral fellowship (WT100066MA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.